Recurrence of Graves' Disease: What Genetics of HLA and PTPN22 Can Tell Us.

ABSTRACT:

Background

Approximately half of patients diagnosed with Graves' disease (GD) relapse within two years of thyreostatic drug withdrawal. It is then necessary to decide whether to reintroduce conservative treatment that can have serious side effects, or to choose a radical approach. Familial forms of GD indicate a significant genetic component. Our aim was to evaluate the practical benefits of HLA and PTPN22 genetic testing for the assessment of disease recurrence risk in the Czech population.

Methods

In 206 patients with GD, exon 2 in the HLA genes DRB1, DQA1, DQB1 and rs2476601 in the gene PTPN22 were sequenced.

Results

The risk HLA haplotype DRB1*03-DQA1*05-DQB1*02 was more frequent in our GD patients than in th

SUBMITTER: Vejrazkova D 

PROVIDER: S-EPMC8650699 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature